220 related articles for article (PubMed ID: 25996455)
1. Small-world networks of residue interactions in the Abl kinase complexes with cancer drugs: topology of allosteric communication pathways can determine drug resistance effects.
Tse A; Verkhivker GM
Mol Biosyst; 2015 Jul; 11(7):2082-95. PubMed ID: 25996455
[TBL] [Abstract][Full Text] [Related]
2. Molecular Dynamics Simulations and Structural Network Analysis of c-Abl and c-Src Kinase Core Proteins: Capturing Allosteric Mechanisms and Communication Pathways from Residue Centrality.
Tse A; Verkhivker GM
J Chem Inf Model; 2015 Aug; 55(8):1645-62. PubMed ID: 26236953
[TBL] [Abstract][Full Text] [Related]
3. Molecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and Coevolution.
Tse A; Verkhivker GM
PLoS One; 2015; 10(6):e0130203. PubMed ID: 26075886
[TBL] [Abstract][Full Text] [Related]
4. Atomistic Modeling of the ABL Kinase Regulation by Allosteric Modulators Using Structural Perturbation Analysis and Community-Based Network Reconstruction of Allosteric Communications.
Astl L; Verkhivker GM
J Chem Theory Comput; 2019 May; 15(5):3362-3380. PubMed ID: 31017783
[TBL] [Abstract][Full Text] [Related]
5. Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.
Tse A; Verkhivker GM
PLoS One; 2016; 11(11):e0166583. PubMed ID: 27861609
[TBL] [Abstract][Full Text] [Related]
6. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Gniot M; Wasilewska EM; Lewandowski K
Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
[No Abstract] [Full Text] [Related]
7. Ensemble-based modeling and rigidity decomposition of allosteric interaction networks and communication pathways in cyclin-dependent kinases: Differentiating kinase clients of the Hsp90-Cdc37 chaperone.
Stetz G; Tse A; Verkhivker GM
PLoS One; 2017; 12(11):e0186089. PubMed ID: 29095844
[TBL] [Abstract][Full Text] [Related]
8. Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases.
Dixit A; Verkhivker GM
PLoS Comput Biol; 2011 Oct; 7(10):e1002179. PubMed ID: 21998569
[TBL] [Abstract][Full Text] [Related]
9. HRD Motif as the Central Hub of the Signaling Network for Activation Loop Autophosphorylation in Abl Kinase.
La Sala G; Riccardi L; Gaspari R; Cavalli A; Hantschel O; De Vivo M
J Chem Theory Comput; 2016 Nov; 12(11):5563-5574. PubMed ID: 27682200
[TBL] [Abstract][Full Text] [Related]
10. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
Tokarski JS; Newitt JA; Chang CY; Cheng JD; Wittekind M; Kiefer SE; Kish K; Lee FY; Borzillerri R; Lombardo LJ; Xie D; Zhang Y; Klei HE
Cancer Res; 2006 Jun; 66(11):5790-7. PubMed ID: 16740718
[TBL] [Abstract][Full Text] [Related]
11. Insight into the allosteric inhibition of Abl kinase.
Fallacara AL; Tintori C; Radi M; Schenone S; Botta M
J Chem Inf Model; 2014 May; 54(5):1325-38. PubMed ID: 24787133
[TBL] [Abstract][Full Text] [Related]
12. Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase".
Jahnke W; Paladini J; Habazettl JM; Wiget A; Loo A; Cowan Jacob SW; Grzesiek S; Manley PW
Angew Chem Int Ed Engl; 2022 Nov; 61(46):e202117276. PubMed ID: 36257909
[TBL] [Abstract][Full Text] [Related]
13. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
14. Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions.
James KA; Verkhivker GM
PLoS One; 2014; 9(11):e113488. PubMed ID: 25427151
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
Healy EF; Johnson S; Hauser CR; King PJ
FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
[TBL] [Abstract][Full Text] [Related]
16. Computational modeling of allosteric regulation in the hsp90 chaperones: a statistical ensemble analysis of protein structure networks and allosteric communications.
Blacklock K; Verkhivker GM
PLoS Comput Biol; 2014 Jun; 10(6):e1003679. PubMed ID: 24922508
[TBL] [Abstract][Full Text] [Related]
17. Allosteric interactions between the myristate- and ATP-site of the Abl kinase.
Iacob RE; Zhang J; Gray NS; Engen JR
PLoS One; 2011 Jan; 6(1):e15929. PubMed ID: 21264348
[TBL] [Abstract][Full Text] [Related]
18. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
19. Probing conformational landscapes and mechanisms of allosteric communication in the functional states of the ABL kinase domain using multiscale simulations and network-based mutational profiling of allosteric residue potentials.
Krishnan K; Tian H; Tao P; Verkhivker GM
J Chem Phys; 2022 Dec; 157(24):245101. PubMed ID: 36586979
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
